About Kenai Therapeutics
Pioneering next generation approaches to cure neurological conditions
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Diego, California
- Founded
- 2022
- Company type
- Privately Held
Kenai Therapeutics is a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions. By leveraging a proprietary, Nobel Prize-winning iPSC platform, Kenai is developing off-the-shelf, allogeneic neuron replacement and gene-modified cell therapies designed to be disease-modifying. Kenai’s lead candidate, RNDP-001, is in Phase 1 clinical development for moderate to moderate-severe forms of idiopathic Parkinson’s disease. The company’s additional programs target inherited and genetically driven subtypes of Parkinson’s disease and other neurological conditions, with the goal of delivering long-lasting restoration of function. Kenai’s exclusive manufacturing partnership with FUJIFILM Cellular Dynamics, Inc., enables scalable, cryopreserved production of high-potency cell therapies. Founded in 2022, Kenai is backed by leading life science investors and is headquartered in San Diego, CA.
Specialties
- Biotechnology
- Cell Therapy
- and Neurodegenerative Diseases
Company locations
San Diego, California, US
Cambridge, MA, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
On LinkedIn
- Followers
- 6,441
- People linked to this company
- 38
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.